<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00598611</url>
  </required_header>
  <id_info>
    <org_study_id>P04805-V2.0</org_study_id>
    <secondary_id>EudraCT number: 2006-003686-13</secondary_id>
    <nct_id>NCT00598611</nct_id>
  </id_info>
  <brief_title>Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU)</brief_title>
  <acronym>AUD2OCU</acronym>
  <official_title>An Exploratory Phase III, Randomised, Double-blind, Therapeutic Single Dose-related Effect, Parallel Group Study to Assess and Compare the Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Essex Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare urticaria lesions (size, kinetics) by thermography,
      volumetry and digital time lapse photography in CU patients treated with desloratadine 5 mg
      or desloratadine 20 mg. Hypothesis: Updosing of desloratadine (20mg) is more efficient in the
      treatment of urticarial lesions as compared to standard dosing (5 mg desloratadine).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in size of existing spontaneous urticaria lesions (wheal and flare) as assessed by thermography.</measure>
    <time_frame>5 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in size of existing spontaneous urticaria lesions (wheal and flare) as assessed by volumetry and digital time lapse photography.</measure>
    <time_frame>5 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Chronic Urticaria</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>desloratadine 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>desloratadine 20 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>desloratadine</intervention_name>
    <description>singel dose, oral, 20 mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>desloratadine</intervention_name>
    <description>single dose, oral, 5 mg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Outpatients with moderate to severe CU for more than 6 weeks. Urticaria symptoms must
             comprise wheal and itch.

          2. Patients must exhibit spontaneous urticaria lesions in the randomization visit.

          3. History of beneficial effects of antihistaminic treatment.

          4. Age between 18 and 60 years.

          5. Female patients must be using adequate contraceptive precautions (highly effective
             method), or they must be postmenopausal, surgically sterilised, or hysterectomised
             (for details please see protocol).

          6. Female patients must be using adequate contraceptive precautions (contraceptive pill,
             depot, double barrier methods), or they must be postmenopausal, surgically sterilised,
             or hysterectomised.

          7. Voluntarily signed written informed consent.

        Exclusion Criteria:

          1. The presence of permanent severe diseases, especially those affecting the immune
             system, except CU.

          2. The presence of permanent gastrointestinal condition which may influence the oral
             therapy (chronic diarrhea diseases, congenital malformations or surgical mutilations
             of the gastrointestinal tract).

          3. History or presence of epilepsy, significant neurological disorders, cerebrovascular
             attacks or ischemia.

          4. History or presence of myocardial infarction or cardiac arrhythmia which requires drug
             therapy.

          5. Evidence of severe renal dysfunction

          6. Evidence of significant hepatic disease (liver enzymes twice the upper reference
             value).

          7. The presence of galactose intolerance, lapp lactase deficiency or glucose galactose
             malabsorption.

          8. History of adverse reactions including hypersensitivity to DL and Loratadine.

          9. Intake of medicaments that could cause QT changes (drugs listed on www.qtdrugs.org).

         10. Presence of active cancer which requires chemotherapy or radiation therapy.

         11. Presence of acute urticaria / angioedema including laryngeal edema

         12. History or presence of alcohol abuse or drug addiction.

         13. Participation in any clinical trial within 4 weeks prior to enrolment.

         14. Intake of oral corticosteroids or other immunosuppressive therapy within 14 days prior
             to the beginning of the study.

         15. Use of depot corticosteroids or chronic systemic corticosteroids within 21 days before
             beginning of the study.

         16. Pregnancy or breast-feeding.

         17. Existing or planned placement in an institution after ruling according to ยง 40 passage
             1 number 4 AMG (Arzneimittelgesetz).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus Maurer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allergie-Centrum-Charite</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergie-Centrum-Charite</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.urtikaria.net</url>
  </link>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2008</study_first_submitted>
  <study_first_submitted_qc>January 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2008</study_first_posted>
  <last_update_submitted>May 30, 2012</last_update_submitted>
  <last_update_submitted_qc>May 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>K. Weller</investigator_full_name>
    <investigator_title>Dr. Karsten Weller</investigator_title>
  </responsible_party>
  <keyword>urticaria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Desloratadine</mesh_term>
    <mesh_term>Loratadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

